Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Thymosin Beta-4 (TB4) is a healing peptide, at the clinical trials (cardiac) stage in the published literature. The full-length 43 amino acid protein that TB-500 is derived from. Naturally occurring in most tissues and plays key roles in tissue repair.
The full-length 43 amino acid protein that TB-500 is derived from. Naturally occurring in most tissues and plays key roles in tissue repair.
| Research Status | Clinical trials (cardiac) |
|---|---|
| Half-Life | Unknown |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 750 mcg - 2 mg |
Sequesters G-actin, promotes cell migration, wound healing, and tissue regeneration through multiple pathways.
The full-length 43 amino acid protein that TB-500 is derived from. Naturally occurring in most tissues and plays key roles in tissue repair.
Sequesters G-actin, promotes cell migration, wound healing, and tissue regeneration through multiple pathways.
Thymosin Beta-4 is at the following stage in the published literature: Clinical trials (cardiac). All information is for research and educational purposes only.
Reported half-life: Unknown.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.